MAPT and tauopathy: We conclude that the set of gene-edited iPSC lines with MAPT IVS10+16 and MAPT IVS10+16/P301S mutations that we described could serve as a platform to identify new targets for drug development and to reveal the mechanisms underlying FTDP-17 and other tauopathies.